تقرير
أعرض في EDS

National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.

التفاصيل البيبلوغرافية
العنوان: National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
المؤلفون: Niciu MJ; University of Iowa Health Care, Department of Psychiatry/Iowa Neuroscience Institute, Iowa City, IA 52242, USA. Electronic address: mark-niciu@uiowa.edu., Meisner RC; McLean Hospital, Psychiatric Neurotherapeutics Program, 115 Mill St., Belmont, MA 02478, USA; Harvard Medical School, Department of Psychiatry, Boston, MA 02115, USA., Carr BR; University of Florida College of Medicine, Department of Psychiatry, Gainesville, FL 32610, USA., Farooqui AA; University of Louisville School of Medicine, Department of Psychiatry and Behavioral Sciences, Louisville, KY 40202, USA., Feifel D; Kadima Neuropsychiatry Institute, La Jolla, CA 92037, USA; University of California San Diego School of Medicine, La Jolla, CA 92093, USA., Kaplin A; Mira Pharmaceuticals, Baltimore, MD 21205, USA; The Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA., Kendrick EJ; University of Utah School of Medicine, Department of Psychiatry, University Neuropsychiatric Institute, Salt Lake City, UT 84132, USA., Kim PM; The Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA., Schneck CD; University of Colorado Anschutz Medical Campus, Department of Psychiatry, Helen and Arthur E. Johnson Depression Center, Aurora, CO 80045, USA., Vande Voort JL; Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN 55905, USA., Parikh SV; University of Michigan School of Medicine, Department of Psychiatry and Depression Center, Ann Arbor, MI 48109, USA.
المصدر: Journal of affective disorders [J Affect Disord] 2024 Feb 01; Vol. 346, pp. 221-222. Date of Electronic Publication: 2023 Nov 06.
نوع المنشور: Letter; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7906073 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2517 (Electronic) Linking ISSN: 01650327 NLM ISO Abbreviation: J Affect Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
مواضيع طبية MeSH: Ketamine*/therapeutic use , Depressive Disorder, Major*/drug therapy , Depressive Disorder, Treatment-Resistant*/drug therapy, Humans ; Depression ; Infusions, Intravenous ; Insurance Coverage
مستخلص: Competing Interests: Declaration of competing interest To the best of our knowledge, the authors have no competing interests, financial or otherwise, salient to the information presented in this Correspondence.
المشرفين على المادة: 690G0D6V8H (Ketamine)
تواريخ الأحداث: Date Created: 20231108 Date Completed: 20231204 Latest Revision: 20240129
رمز التحديث: 20240129
DOI: 10.1016/j.jad.2023.11.008
PMID: 37940059
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-2517
DOI:10.1016/j.jad.2023.11.008